Product Images Risedronate Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Risedronate Sodium NDC 60723-041 by Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
image description - carton 12 ct
This is a description of a medication called "Once-a-Week" with the NDC (National Drug Code) number 60723-041-12. The medication contains 35mg of Risedronate Sodium and is in tablet form. The package contains a 12-week supply and each unit contains 4 tablets. There are instructions on how to take the medication, but there is some gibberish mixed in due to (Optical Character Recognition) errors.*
image description - carton 4 ct
Risedronate Sodium Tablets, USP are recommended for the treatment of osteoporosis. The medication guide enclosed in the package should be dispensed to each patient. This is a 4 Week Supply of Rx only 414 Unit of Use Tablets. The text does not provide more information, as some characters are unreadable.*
image description - figure 1
image description - figure 2
The text describes a figure (Figure 2) showing the change in BMD (bone mineral density) from baseline in a study about prevention over the course of 2 years. The BMD data is displayed in the form of a graph with mean % change and standard error (SE) values. The figure includes data points for the lumbar spine, femoral neck, and trochanter. However, due to errors, some of the text appears nonsensical (e.g. "o] ClPecsbo W risearonae soaum").*
image description - figure 3
This appears to be a figure from a study showing the change in bone mineral density (BMD) from baseline in patients who recently initiated glucocorticoid therapy. The figure compares the changes observed with placebo, Risedronate Sodium 5 mg, and other treatments. The BMD changes are shown for different parts of the body including the lumbar spine, femoral neck, and trochanter.*
image description - figure 4
The text describes a figure (Figure 4) that shows the change in bone mineral density (BMD) from baseline in patients on long-term glucocorticoid therapy. The figure displays BMD data for a placebo group and a group taking Risedronate Sodium 5mg. The BMD values are provided for lumbar spine, femoral neck, and trochanter. SE is also mentioned in the figure.*
image description - figure 5
The text is a table or figure and does not provide a useful description.*
image description - figure 6
image description - risedronate sodium
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.